FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4232857360> ?p ?o ?g. }

• W4232857360 abstract "Abstract Background Malaria is a major public health problem in Togo. Guangzhou University of Chinese medicine of China, and the Ministry of Health and Social Security of Togo launched a nationwide artemisinin compound Mass Drug Administration Project in East Mono with a population of 150,000. Before launching the project, the sensitivity test of artemisinin piperaquine tablet was conducted in Elawagnon general clinic. On this background, we evaluated the efficacy and safety of artemisinin piperaquine in the treatment of uncomplicated falciparum malaria in children under five years of age. Methods In this study, children aged 6-59 months without complications of falciparum malaria were observed, and the selected cases were treated with artemisinin piperaquine. The patients were followed up for 28 days to observe the fever clearance time, parasitemia, gametophyte, cure rate, haemoglobin and msp-2 gene polymorphism. The primary end point was the 28-day cure rate, and PCR corrected reinfection and recrudescence. This research was conducted according to standardized WHO protocol for the assessment of the efficacy of anti-malarial treatment. Results A total of 91 children participated in the study. The adequate clinical and parasitological response (ACPR) before PCR-corrected were 66 (72.52%) and 90 (98.90%) after PCR-corrected. The patient was well tolerated to artemisinin piperaquine and no serious adverse reactions were observed. The average hemoglobin level increased by 0.05g/dl per day (p< 0.0001). The gametophyte doesn’t declined at the beginning of treatment, however, 14 days later, it dropped(D21:p<0. 05; D28: p< 0. 01). In the msp-2 gene polymorphism study of 24 children with positive parasite after treatment, 1 case of msp-2 with 3D7 haplotype and FC27 haplotype was reported, indicating that it’s recrudescence, with a frequency of 4.2% (1/24); The others maybe reinfection, with a frequency of 95.8% (23/24). Conclusion Artemisinin piperaquine was effective in treating uncomplicated falciparum malaria in children under 5 years of age in Togo and well tolerated. Plasmodium falciparum in Togo remains sensitive to artemisinin piperaquine, which could be used as a trial drug in the region. Trial Registration Trial registration: ECGPHCM No. B2017-054-01; MHSST AVIS N° 0001/2016/CBRS du 07 janvier 2016. Registered 17 March 2014, http://www.chinadrugtrials.org.cn/eap/main" @default.
• W4232857360 created "2022-05-12" @default.
• W4232857360 creator A5012276389 @default.
• W4232857360 creator A5015195367 @default.
• W4232857360 creator A5026095229 @default.
• W4232857360 creator A5030158048 @default.
• W4232857360 creator A5039524325 @default.
• W4232857360 creator A5045751633 @default.
• W4232857360 creator A5046214153 @default.
• W4232857360 creator A5048963620 @default.
• W4232857360 creator A5050008957 @default.
• W4232857360 creator A5057755317 @default.
• W4232857360 creator A5064540145 @default.
• W4232857360 creator A5064758708 @default.
• W4232857360 creator A5065421769 @default.
• W4232857360 creator A5070695035 @default.
• W4232857360 creator A5073046343 @default.
• W4232857360 creator A5073815918 @default.
• W4232857360 creator A5075109575 @default.
• W4232857360 creator A5090826983 @default.
• W4232857360 date "2020-01-03" @default.
• W4232857360 modified "2023-09-27" @default.
• W4232857360 title "Surveillance of the efficacy of artemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum among children under five years in Est Mono district, Togo, 2017" @default.
• W4232857360 doi "https://doi.org/10.21203/rs.2.19939/v1" @default.
• W4232857360 hasPublicationYear "2020" @default.
• W4232857360 type Work @default.
• W4232857360 citedByCount "0" @default.
• W4232857360 crossrefType "posted-content" @default.
• W4232857360 hasAuthorship W4232857360A5012276389 @default.
• W4232857360 hasAuthorship W4232857360A5015195367 @default.
• W4232857360 hasAuthorship W4232857360A5026095229 @default.
• W4232857360 hasAuthorship W4232857360A5030158048 @default.
• W4232857360 hasAuthorship W4232857360A5039524325 @default.
• W4232857360 hasAuthorship W4232857360A5045751633 @default.
• W4232857360 hasAuthorship W4232857360A5046214153 @default.
• W4232857360 hasAuthorship W4232857360A5048963620 @default.
• W4232857360 hasAuthorship W4232857360A5050008957 @default.
• W4232857360 hasAuthorship W4232857360A5057755317 @default.
• W4232857360 hasAuthorship W4232857360A5064540145 @default.
• W4232857360 hasAuthorship W4232857360A5064758708 @default.
• W4232857360 hasAuthorship W4232857360A5065421769 @default.
• W4232857360 hasAuthorship W4232857360A5070695035 @default.
• W4232857360 hasAuthorship W4232857360A5073046343 @default.
• W4232857360 hasAuthorship W4232857360A5073815918 @default.
• W4232857360 hasAuthorship W4232857360A5075109575 @default.
• W4232857360 hasAuthorship W4232857360A5090826983 @default.
• W4232857360 hasBestOaLocation W42328573601 @default.
• W4232857360 hasConcept C126322002 @default.
• W4232857360 hasConcept C187212893 @default.
• W4232857360 hasConcept C203014093 @default.
• W4232857360 hasConcept C2776120307 @default.
• W4232857360 hasConcept C2777616469 @default.
• W4232857360 hasConcept C2778048844 @default.
• W4232857360 hasConcept C2778371730 @default.
• W4232857360 hasConcept C2908647359 @default.
• W4232857360 hasConcept C71924100 @default.
• W4232857360 hasConcept C99454951 @default.
• W4232857360 hasConceptScore W4232857360C126322002 @default.
• W4232857360 hasConceptScore W4232857360C187212893 @default.
• W4232857360 hasConceptScore W4232857360C203014093 @default.
• W4232857360 hasConceptScore W4232857360C2776120307 @default.
• W4232857360 hasConceptScore W4232857360C2777616469 @default.
• W4232857360 hasConceptScore W4232857360C2778048844 @default.
• W4232857360 hasConceptScore W4232857360C2778371730 @default.
• W4232857360 hasConceptScore W4232857360C2908647359 @default.
• W4232857360 hasConceptScore W4232857360C71924100 @default.
• W4232857360 hasConceptScore W4232857360C99454951 @default.
• W4232857360 hasLocation W42328573601 @default.
• W4232857360 hasOpenAccess W4232857360 @default.
• W4232857360 hasPrimaryLocation W42328573601 @default.
• W4232857360 hasRelatedWork W11597529 @default.
• W4232857360 hasRelatedWork W13105838 @default.
• W4232857360 hasRelatedWork W18851351 @default.
• W4232857360 hasRelatedWork W18919525 @default.
• W4232857360 hasRelatedWork W2840560 @default.
• W4232857360 hasRelatedWork W314393 @default.
• W4232857360 hasRelatedWork W4223913 @default.
• W4232857360 hasRelatedWork W6698722 @default.
• W4232857360 hasRelatedWork W8391359 @default.
• W4232857360 hasRelatedWork W8799533 @default.
• W4232857360 isParatext "false" @default.
• W4232857360 isRetracted "false" @default.
• W4232857360 workType "article" @default.